Press Release: Novartis to highlight Rhapsido(R) data across multiple immune-mediated diseases at EAACI Congress 2026

-- Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentation -- New Phase IIIb REMIXED extension data in...

www.finanzen.ch

Zum Originalartikel